Darifenacin
- Generic Name
- Darifenacin
- Brand Names
- Emselex, Enablex
- Drug Type
- Small Molecule
- Chemical Formula
- C28H30N2O2
- CAS Number
- 133099-04-4
- Unique Ingredient Identifier
- APG9819VLM
- Background
Darifenacin (Enablex®, Novartis) is a medication used to treat urinary incontinence.
Darifenacin blocks M3 muscarinic acetylcholine receptors, which mediate bladder muscle contractions. This block reduces the urgency to urinate and so it should not be used in people with urinary retention.
It is unknown if M3 receptor selectivity is clinically advantageous in overactive bladder syndrome treatments.
- Indication
For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.
- Associated Conditions
- Overactive Bladder Syndrome (OABS)
Darifenacin x Parasacral Transcutaneous Electric Nerve Stimulation for OAB in Patients Infected With Human T-Lymphotropic Virus 1
- Conditions
- HTLV-1Overactive Bladder Syndrome
- Interventions
- Device: Neuromodulation - Sacral nerve stimulation
- First Posted Date
- 2024-09-27
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Hospital Universitário Professor Edgard Santos
- Target Recruit Count
- 42
- Registration Number
- NCT06616675
- Locations
- 🇧🇷
Ambulatório de HTLV-1 - Com HUPES, Salvador, Ba, Brazil
A Study to Assess the Safety, Tolerability, and Pharmacology of Darifenacin in Patients With ALS
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- First Posted Date
- 2024-02-08
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- McGill University
- Target Recruit Count
- 30
- Registration Number
- NCT06249867
- Locations
- 🇨🇦
Montreal Neurological Institute, Montréal, Quebec, Canada
Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania
- Conditions
- Overactive Bladder (OAB)
- Interventions
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Astellas Pharma Singapore Pte. Ltd.
- Target Recruit Count
- 5589
- Registration Number
- NCT03602508
- Locations
- 🇦🇺
Site AU10000, Sydney, Australia
🇰🇷Site KR82001, Seoul, Korea, Republic of
A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China
- Conditions
- Overactive Bladder (OAB)
- Interventions
- Device: solifenacinDevice: propiverine
- First Posted Date
- 2018-06-28
- Last Posted Date
- 2020-04-22
- Lead Sponsor
- Astellas Pharma Singapore Pte. Ltd.
- Target Recruit Count
- 805
- Registration Number
- NCT03572231
- Locations
- 🇰🇷
Site KR410008, Daejeon, Korea, Republic of
🇰🇷Site KR410009, Incheon, Korea, Republic of
🇰🇷Site KR410005, Kangam, Korea, Republic of
Efficacy of Darifenacin and Physiotherapy for the Treatment of Overactive Bladder in Women
- First Posted Date
- 2014-05-21
- Last Posted Date
- 2016-05-02
- Lead Sponsor
- Universidad de Valparaiso
- Target Recruit Count
- 80
- Registration Number
- NCT02143570
- Locations
- 🇨🇱
Hospital Carlos Van Buren, Valparaiso, Chile
Single Dose Bioequivalence Study of Darifenacin Tablets 7.5 mg in Fed Healthy Volunteers.
- First Posted Date
- 2010-10-27
- Last Posted Date
- 2010-10-27
- Lead Sponsor
- Center for Clinical Pharmacology Research Bdbeq S.A.
- Target Recruit Count
- 24
- Registration Number
- NCT01229280
- Locations
- 🇺🇾
Center for Clinical Pharmacology Research (CCPR) Bdbeq S.A. Hospital Italiano., Montevideo, Uruguay
Single Dose Two-periods Crossover Bioequivalence Study of Darifenacin Tablets in Healthy Volunteers.
- First Posted Date
- 2010-10-25
- Last Posted Date
- 2010-10-25
- Lead Sponsor
- Center for Clinical Pharmacology Research Bdbeq S.A.
- Target Recruit Count
- 24
- Registration Number
- NCT01227811
- Locations
- 🇺🇾
Center for Clinical Pharmacology Research Bdbeq S.A.; Hospital Italiano de Montevideo.., Montevideo, Uruguay
Preoperative Use of Darifenacin (Enablex) to Alleviate Postoperative Ureteral Stent Pain
- Conditions
- Overactive BladderRenal ColicPain, Postoperative
- Interventions
- First Posted Date
- 2010-08-26
- Last Posted Date
- 2016-11-21
- Lead Sponsor
- University of Missouri-Columbia
- Target Recruit Count
- 3
- Registration Number
- NCT01189071
- Locations
- 🇺🇸
University of Missouri Healthcare, Columbia, Missouri, United States
Exploratory Study Evaluating the Effects of Darifenacin on Nocturia, Sleep and Daytime Wakefulness
- First Posted Date
- 2009-11-23
- Last Posted Date
- 2016-04-13
- Lead Sponsor
- Cognitive Research Corporation
- Registration Number
- NCT01018225
FREEDOM - First Real-Life Evaluation of Enablex Done in ZA Overactive Bladder Patients During a 3 Months Period
- First Posted Date
- 2009-06-16
- Last Posted Date
- 2015-04-20
- Lead Sponsor
- Bayer
- Target Recruit Count
- 9
- Registration Number
- NCT00921245
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.